Pfizer Inc. (PFE)
1 Green Flag That's Also a Red Flag for Pfizer Stock
An activist investor has correctly identified a dysfunctional area of the business.
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?
Those who own Pfizer's stock may stay invested to see how Pfizer's new growth drivers perform.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Pfizer Stock a Bargain for Long-Term Investors?
Wall Street's bearish take on this proven innovator may not be warranted.
This Beaten-Down Stock Just Gave Investors More Good News: Is it a Buy?
Slowly but surely, the company's prospects are looking more attractive.
3 Potential Catalysts That Could Lift Pfizer Stock Before 2025
The pipeline could yield a winner, but so could a few organizational changes.
Pfizer Is A Good Stock To Buy After The Earnings
PFE has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Investors have not taken the earnings news too positively, however, because significant portion of the growth has been driven by Covid-19 related products or non-recurring items. Based on a single stage dividend discount model and a set of traditional price multiples, PFE appears to be undervalued.
Baby Boomers: 2 Super-High-Yield Stocks to Watch in November
Baby Boomer investors who aren't happy with the falling rates on their savings and CDs may be enticed by the dividend stocks right about now.
Pfizer: Overstated Pessimism Makes Little Sense
Pfizer scored a double beat on revenue and adjusted EPS, bolstered by the surprising performance of its COVID franchise. Despite that, the lukewarm post-earnings response suggests Pfizer needs to flex its muscles on its ex-COVID growth optionalities. PFE has likely moved past its long-term lows in early 2024, underscoring the market's conviction that the worst is over.
Pfizer CEO on Q3 earnings, exceptional with phenomenal growth
After Pfizer (PFE) posted a third quarter earnings beat and raised its full-year guidance, CEO Albert Bourla joins Market Domination to discuss the "exceptional quarter." Bourla notes that Pfizer in addition to earnings and revenue, the company's COVID and non-COVID businesses also topped expectations.
3 Factors That Make Pfizer's Ultra-High-Yield Dividend Safer Than You Might Think
Pfizer's dividends should keep flowing and growing.
Pfizer Covid sales boost prompts durability concerns - Bank of America
Pfizer Inc (NYSE:PFE, ETR:PFE)'s reliance on a rebound in demand for Covid-19 products in expectation-beating third-quarter results likely hit sentiment, according to Bank of America analysts. Though the drug maker hiked guidance on better-than-estimated revenue on Tuesday, shares fell by 1.8% following the results.
